Summary & Overview

HCPCS U0002: SARS-CoV-2 Multi-Target Molecular Test (Non-CDC)

HCPCS Level II code U0002 represents non-CDC molecular diagnostic testing for SARS-CoV-2 that detects multiple viral targets. This code was introduced early in the COVID-19 pandemic to identify infections using assays that target several regions of the viral genome, enabling broader detection across variants. Nationally, accurate lab coding for COVID-19 tests affects surveillance, payer reimbursement, and data aggregation for public health reporting.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for U0002, benchmarks and typical site-of-service expectations for molecular laboratory testing, and discussion of the policy and billing implications tied to non-CDC multi-target assays. The summary highlights common modifiers associated with laboratory services and notes when additional technical or professional components may apply.

The publication details coding considerations, payer coverage patterns, and operational notes relevant to laboratories and health system billing teams. Where specific payer contract terms or payment rates are not available in the input, the document indicates that such data is not provided.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareU0002HCPCS Level IISARS-CoV-2COVID-19 testingmolecular diagnosticslaboratorymulti-target assaynon-CDC tests

Billing Code Overview

HCPCS Level II code U0002 describes testing for 2019-nCoV coronavirus, SARS-CoV-2/2019-nCoV (COVID-19) using any technique that detects multiple types or subtypes (includes all targets), non-CDC. The code represents laboratory diagnostic testing designed to identify SARS-CoV-2 genetic material across multiple viral targets when performed by non-CDC laboratories.

Service Type: Clinical laboratory diagnostic test for SARS-CoV-2 using nucleic acid or other molecular techniques capable of detecting multiple targets.

Typical Site of Service: Clinical laboratory or hospital laboratory performing molecular diagnostic testing. Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult who presents to an outpatient urgent care clinic, community testing site, or hospital ambulatory collection area with symptoms consistent with an acute respiratory infection (fever, cough, sore throat, myalgias) or with known exposure to a confirmed SARS-CoV-2 case. A clinician or trained medical assistant collects a nasopharyngeal or nasal swab and sends the specimen to a non-CDC laboratory performing multiplex or multi-target molecular testing for SARS-CoV-2 that includes detection of multiple viral targets or subtypes. The workflow includes patient registration, verification of order and insurance, specimen collection with appropriate personal protective equipment, specimen labeling and transport to the laboratory, test performance using a non-CDC EUA-approved assay, result verification by laboratory personnel, and result reporting to the ordering provider and public health authorities as required. Typical sites of service include outpatient clinics, urgent care centers, hospital outpatient departments, community testing sites, and commercial reference laboratories.

Coding Specifications

Modifier	Description	When to Use
`91`	Repeat clinical diagnostic lab test	When a repeat SARS-CoV-2 test is performed on the same day for confirmation or serial monitoring
`90`

Taxonomy Code	Specialty	Notes
363L00000X	Infectious Disease	Interpretation of complex infectious disease testing and consultation
207L00000X	Internal Medicine	Ordering and managing outpatient diagnostic testing for adult patients
208D00000X	Emergency Medicine	Ordering rapid diagnostic testing in urgent or emergency settings
208000000X	Family Medicine	Primary care ordering and follow-up of SARS-CoV-2 testing
261QM2500X	Clinical Laboratory	Performing and reporting laboratory testing and assays

ICD-10 Code	Description	Clinical Relevance
`J12.82`	Pneumonia due to coronavirus disease 2019	Indicates lower respiratory tract infection due to SARS-CoV-2; supports testing and further management
`U07.1`	COVID-19	Primary diagnosis for confirmed COVID-19 infection; directly indicates SARS-CoV-2 testing and reporting
`R05`	Cough	Common presenting symptom prompting SARS-CoV-2 testing in symptomatic patients
`R50.9`	Fever, unspecified	Fever is a common symptom leading to diagnostic testing for SARS-CoV-2
`Z20.822`	Contact with and (suspected) exposure to COVID-19	Encounters for exposure or contact tracing where SARS-CoV-2 testing is indicated

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Often performed when concurrent laboratory studies (e.g., serology, CBC) are ordered with SARS-CoV-2 molecular testing
`99000`	Handling and/or conveyance of specimen for transfer from office to laboratory	Used when a facility documents specimen transport or courier services to an outside lab performing the assay
`G2023`	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), at a drive-through testing collection site, single specimen	Commonly billed for collection services at dedicated drive-through or community testing locations
`G2024`	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), at a drive-through testing collection site, up to 25 specimens per day	Used by testing sites managing multiple specimens per day for logistical billing
`87635`	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (e.g., COVID-19), amplified probe technique	Commonly used alternative CPT code when reporting SARS-CoV-2 molecular testing in CPT coding systems; relates directly to the molecular assay performed under `U0002`

OpenPayer